Thymosin Alpha-1: Immunomodulation and Why It Is Not TB-500

Two peptides share a family name and almost nothing else. Thymosin alpha-1 is a 28-residue peptide that acts on immune cell signalling. Thymosin beta-4, the molecule behind the research construct sold as TB-500, is a 43-residue actin-binding protein with an entirely intracellular function. They are not isoforms of one molecule. They are unrelated sequences pulled from the same crude thymus extract in the 1970s and named according to the order in which they came off a column. That accident of nomenclature is the single largest source of error in the material written about both.

Thymosin fraction 5 and an accident of naming

In 1972 Allan Goldstein and colleagues described a partially purified preparation from calf thymus that restored immune function in thymectomised mice 1. They called it thymosin fraction 5. It was not a single molecule. It was a mixture of somewhere between thirty and forty distinct polypeptides, separated from the rest of the extract by ammonium sulphate precipitation and gel filtration, then held under one name because at that stage nobody could say which component was responsible for which activity.

The convention adopted for naming the components was isoelectric focusing. Peptides with an isoelectric point below 5.0 were assigned to the alpha group, those between 5.0 and 7.0 to the beta group, and those above 7.0 to the gamma group. The number that followed recorded the order of characterisation within a group. Thymosin alpha-1 was therefore the first acidic component to be isolated and sequenced 2. Thymosin beta-4 was the fourth peptide characterised in the intermediate band.

The shared name encodes exactly one piece of information: how the two peptides behaved in an electric field in the 1970s. It says nothing about sequence homology, because there is none. It says nothing about shared receptors, pathways, tissue distribution or function. The peptides are not variants of a common gene product. They are separate proteins that happened to co-purify from the same starting material because both are small, both are soluble, and both survived the same crude preparation.

The practical consequence is large. Material about thymosin alpha-1, including its regulatory status and its clinical trial record, is routinely attached in secondary sources to thymosin beta-4 and by extension to the research construct marketed as TB-500. Those bodies of evidence do not transfer between molecules. A licensed indication for one peptide tells you nothing whatsoever about the other.

The molecule, and where it comes from

Thymosin alpha-1 is 28 amino acids long, acetylated at the N-terminus, and strongly acidic, its sequence being rich in glutamate and aspartate 2. It contains no cysteine, so it forms no disulphide bonds, and in aqueous solution it is largely unstructured. Ordered conformation appears to depend on environment: the peptide adopts more defined secondary structure in membrane-mimetic solvents than it does in water, which is consistent with a molecule whose function involves contact with a cell surface.

It is not translated as a standalone gene product. Thymosin alpha-1 corresponds to the first 28 residues of prothymosin alpha, a 109-residue nuclear protein encoded by the PTMA gene and expressed in essentially every mammalian tissue examined. Whether the 28-residue fragment is a genuine physiological cleavage product with a signalling role, or largely an artefact of proteolysis during extraction, was argued over for years and is not fully settled. What is not disputed is that the synthetic 28-mer has reproducible biological activity in cell and animal systems.

The synthetic peptide is made by solid-phase synthesis and appears in the clinical literature under the international nonproprietary name thymalfasin. Papers using that term and papers using thymosin alpha-1 describe the same molecule, and the two literatures should be read together rather than treated as separate fields.

Toll-like receptor signalling and dendritic cell maturation

For two decades after its isolation, thymosin alpha-1 was described as an immune modulator with no defined receptor. The most durable mechanistic account arrived in 2004, from work in a murine model of invasive aspergillosis reporting that the peptide acted on dendritic cells through Toll-like receptor signalling 3. Dendritic cells are the antigen-presenting cells that determine how a naive T cell differentiates, so an agent acting at that point can shape an entire downstream response without acting on T cells directly.

In that work the effect was lost in animals lacking MyD88, the adaptor protein sitting immediately downstream of most Toll-like receptors, and was attributed principally to TLR9 with a contribution from TLR2 3. Treated dendritic cells upregulated interleukin-12 and shifted towards a phenotype that polarises T cells along the Th1 axis, the arm of the response that matters for intracellular pathogens and fungi. Fungal killing improved and survival increased in the treated animals.

The T-cell effects reported across the older literature follow from this rather than constituting a separate mechanism. Thymosin alpha-1 has been described as increasing the proportion of mature CD4-positive and CD8-positive cells, raising interleukin-2 receptor expression, and enhancing natural killer cell activity. Restoration of T-cell numbers in thymectomised and immunosuppressed animals was what fraction 5 was originally selected for, and it remains the most consistently reproduced observation in the field 1.

Two limits should be stated plainly. The receptor-level mechanism was established in mice and in cultured cells, not in humans. And the direction of effect is context-dependent: a peptide that amplifies Th1 polarisation in an infected animal is not doing the same thing in an uninfected one. Reports of thymosin alpha-1 restoring depressed immune function considerably outnumber reports of it producing any measurable change in a normal immune system, and that asymmetry is a property of the compound rather than a gap in the literature.

Approved use, and the trials behind it

Thymalfasin is a licensed medicine in roughly thirty countries, with chronic hepatitis B and chronic hepatitis C the most common approved indications and use as an adjuvant to influenza and hepatitis B vaccination permitted in some jurisdictions. It has not been approved by the United States Food and Drug Administration or by the European Medicines Agency. That asymmetry is itself informative. The compound has cleared regulatory review where the evidentiary standard allowed it to, and has not cleared the two most demanding ones.

The hepatitis literature is the largest body of controlled work and it is genuinely mixed. Individual randomised trials and several meta-analyses have reported improved sustained virological response when the peptide was added to an interferon-based regimen. Others found no significant advantage. The trials were mostly small, ran across different viral genotypes and different background therapies, and predate the direct-acting antivirals that have since transformed hepatitis C treatment. That last point carries real weight: an adjunct evaluated against a backbone that is no longer standard of care tells you little about current practice.

The most-cited critical care result is a multicentre randomised trial in severe sepsis, which reported 28-day mortality of 26.0 percent in the treated arm against 35.0 percent with standard care 4. That is a difference worth noticing, and it did not reach the conventional threshold for statistical significance. The trial was single-blind and modest in size. It supports continued investigation. It does not establish efficacy, and the authors did not claim that it did.

This is the pattern across the therapeutic literature for this peptide: a large number of small positive signals, very few adequately powered confirmatory trials, and an unusual concentration of the evidence base in the countries where the compound is marketed. None of that is disqualifying. It does mean the honest summary is promising and unconfirmed rather than established.

The direct contrast with thymosin beta-4

Thymosin beta-4 works by binding monomeric actin. It is the principal G-actin sequestering protein in most mammalian cells, holding a large intracellular pool of unpolymerised actin in reserve and releasing it when the cell needs to build filaments 5. That is a cytoskeletal function, exerted inside the cell, on a structural protein. Its cytoplasmic concentration is high, in the tens of micromolar, because a buffering role requires stoichiometric quantities rather than catalytic ones.

Thymosin alpha-1 does none of this. It has no reported affinity for actin, and the mechanism described for it is receptor-mediated signalling at the surface of an immune cell, active at concentrations orders of magnitude lower 3. The two peptides differ in length, in charge, in gene of origin, in cellular compartment, in effective concentration range, and in the entire class of mechanism proposed for them. What they share is a prefix.

One further distinction is the one most often lost. TB-500 is not thymosin beta-4 either. It is a shorter synthetic construct built around an active fragment of that sequence, and its properties cannot simply be inherited from the full-length protein. A claim that begins with a thymosin alpha-1 clinical trial and finishes at a vial labelled TB-500 has crossed two separate molecules, not one.

What the primary literature supports for thymosin alpha-1 is narrower than the secondary literature suggests, and the boundaries are worth setting out explicitly.

• The receptor-level mechanism, meaning Toll-like receptor engagement on dendritic cells and subsequent Th1 polarisation, rests on murine and in vitro work. There is no equivalent human mechanistic dataset.
• Approval in some jurisdictions is not evidence of efficacy in indications where the compound has not been tested, and regulatory standards differ substantially between agencies.
• The hepatitis trials that generated most of the positive signal used interferon backbones that are no longer standard treatment, which limits how far those results carry.
• The sepsis result comes from a single single-blind trial whose primary comparison fell short of statistical significance and has not been confirmed by an adequately powered replication.
• No property demonstrated for thymosin alpha-1 transfers to thymosin beta-4, and none transfers to TB-500.

None of that makes the peptide uninteresting. A molecule with a defined mechanism at a defined receptor class, a five-decade research record and a licensed formulation in multiple countries is a considerably better characterised object than most of what gets discussed in this field. It is simply a different object from the one it is habitually confused with, and keeping the two apart is the precondition for reading either literature accurately.